Market Access Essentials Pricing & Reimbursement Strategy

Market Access | Regulatory Affairs | HEOR | RWE | HTA | Health Economics | Pharma
What you'll learn
Decode payer decision drivers and predict HTA outcomes using proven frameworks.
Map IRP cascades across countries and prevent significant global price erosion.
Calculate optimal launch windows that substantially boost lifetime revenue potential.
Reduce gross-to-net leakage through strategic channel and contract management.
Design outcome-based MEAs that secure premium pricing while ensuring payer acceptance.
Build dynamic pricing models using Monte Carlo and scenario planning techniques.
Anticipate competitive moves using game theory to protect market positioning.
Create integrated launch plans that align regulatory, market access, and supply chain.
Execute a multi-market simulation and benchmark against proven optimal strategies.
Master tools to defend billions in revenue throughout a drug's entire lifecycle.
Requirements
No requirements
Description
Disclaimer: This course contains the use of artificial intelligence.Launch Fast, Lose Billions: Master the Dark Art of Pharma Market AccessEvery $1 of list price you announce triggers a global chain reaction. A €50,000 price in Italy becomes €8,000 in Brazil within 42 days. A rushed Alzheimer's launch cost one company $4.2 billion-95% of projected revenue. The problem? You're optimizing for speed while the market is optimizing for your failure.This isn't a course about rebates and paperwork. It's a strategic weapons system for pricing leaders who refuse to let 40-60% of revenue vanish through PBM black boxes, 340B traps, and IRP cascades.Across six integrated modules, you'll deconstruct real-world catastrophes (a $2.3B pricing disaster), reverse-engineer billion-dollar successes (GeneCure's $1.2M gene therapy MEA), and master the mathematical models that predict payer behavior with 80% accuracy.What You'll Build:IRP Propagation Models that map how a price change in Portugal ripples to 37 countriesLaunch Sequencing Algorithms that calculate the exact 6-month stabilization window worth $180MGross-to-Net Defense Systems to claw back $20-40M annually from DIR fees and contract pharmacy leakageOutcome-Based MEA Contracts that turn "your drug is too expensive" into "we'll pay $100K if it works"The capstone simulation throws you into the hot seat: Navigate a Korean competitor ambush, choreograph a 5-market launch, and see your decisions hit real-time P&L. Score yourself against the $418M optimal blueprint.If you're done leaving billions on the table, this is your playbook.
Who this course is for
Designed for Market Access, HEOR, RA, Clinical, Biostats, and Medical Writing leaders
Homepage